medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2026, Number 1

<< Back Next >>

Acta Med 2026; 24 (1)

The new approach to heart failure with preserved ejection fraction. Pathophysiology and diagnosis

Díaz GEJ, Sánchez AR, Bautista MB, Pérez SK, Regules SS

Language: Spanish
References: 33
Page: 47-53
PDF size: 276.70 Kb.


ABSTRACT

Heart failure with preserved ejection fraction (HFpEF) is a multifactorial pathology that represents a significant and increasing proportion of all clinical presentations of heart failure (HF); it is associated with high morbidity and mortality and an overall survival of 50% at five years after diagnosis. HFpEF is characterized by diastolic dysfunction that is generated early and conditioned by associated comorbidities, structural and cellular changes, and the presentation of a concentric remodeling phenotype accompanied by pressure overload. It consists of signs and symptoms typical of HF and elevated natriuretic peptides, but with a different cardiac phenotype, without evidence of alteration of ejection fraction, so its diagnosis is made by the association of the clinical, laboratory studies, and demonstration of cardiac involvement. Current treatment focuses on two main objectives: the regression of the symptoms of diastolic dysfunction and the reduction of predisposing factors.


REFERENCES

  1. Ventura HO, Lavie CJ, Mehra MR. Heart failure with preserved ejection fraction: separating the wheat from the chaff. J Am Coll Cardiol. 2020; 75 (3): 255-257. Available in: http://dx.doi.org/10.1016/j.jacc.2019.11.027

  2. Kittleson MM. Heart failure with reduced ejection fraction: what's new in the 2022 guideline? Cleve Clin J Med. 2023; 90 (4): 215-220. Available in: http://dx.doi.org/10.3949/ccjm.90a.22101

  3. Correction to: 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2023; 147 (14): e674. Available in: http://dx.doi.org/10.1161/CIR.0000000000001142

  4. Chatterjee K. Pathophysiology of systolic and diastolic heart failure. Med Clin North Am. 2012; 96 (5): 891-899. Available in: http://dx.doi.org/10.1016/j.mcna.2012.07.001

  5. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362 (9386): 759-766. Available in: http://dx.doi.org/10.1016/s0140-6736(03)14282-1

  6. Aurigemma GP, Gaasch WH. Diastolic heart failure. N Engl J Med. 2004; 351 (11): 1097-1105. Available in: http://dx.doi.org/10.1056/nejmcp022709

  7. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007; 28 (20): 2539-2550. Available in: http://dx.doi.org/10.1093/eurheartj/ehm037

  8. Obokata M, Reddy YNV, Borlaug BA. Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods. JACC Cardiovasc Imaging. 2020; 13 (1 Pt 2): 245-257. Available in: http://dx.doi.org/10.1016/j.jcmg.2018.12.034

  9. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017; 14 (10): 591-602. Available in: http://dx.doi.org/10.1038/nrcardio.2017.65

  10. Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021; 128 (10): 1421-1434. Available in: http://dx.doi.org/10.1161/circresaha.121.318172

  11. Anguita SM, Pineda SO. Diagnosis and therapy for diastolic heart failure. Rev Esp Cardiol (Engl Ed). 2004; 57 (6): 570-575. Available in: http://dx.doi.org/10.1016/s1885-5857(06)60631-2

  12. Arrigo M, Jessup M, Mullens W, Reza N, Shah AM, Sliwa K et al. Acute heart failure. Nat Rev Dis Primers. 2020; 6 (1): 16. Available in: http://dx.doi.org/10.1038/s41572-020-0151-7

  13. Alcocer GMA, Borrayo SG, Gutiérrez FP, Tepayotl AA, Ruiz RVE, Castán FD, et al. Primera declaración mexicana en materia de insuficiencia cardiaca. Cardiovasc Metab Sci. 2021; 32 (S1): s8-s85. Available in: http://dx.doi.org/10.35366/98870

  14. Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021; 11 (1): 263-276. Available in: http://dx.doi.org/10.21037/cdt-20-302

  15. Omote K, Verbrugge FH, Borlaug BA. Heart failure with preserved ejection fraction: Mechanisms and treatment strategies. Annu Rev Med. 2022; 73 (1): 321-337. Available in: http://dx.doi.org/10.1146/annurev-med-042220-022745

  16. Magaña-Serrano JA, Rosas-Peralta M, Candanosa-Arias C, Valencia-Sánchez S, Garrido-Garduño M, Arriaga-Nava R et al. Insuficiencia cardiaca con fracción de expulsión preservada (ICFEP). Impacto del cambio en el paradigma de la disfunción diastólica aislada. Gac Med Mex. 2015; 151: 635-647. Disponible en: https://www.anmm.org.mx/GMM/2015/n5/GMM_151_2015_5_635-647.pdf

  17. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020; 17 (9): 559-573. Available in: http://dx.doi.org/10.1038/s41569-020-0363-2

  18. Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022; 27 (2): 625-643. Available in: http://dx.doi.org/10.1007/s10741-021-10105-w

  19. Tzanetos K, Leong D, Wu RC. Office management of patients with diastolic heart failure. CMAJ. 2009; 180 (5): 520-527. Available in: http://dx.doi.org/10.1503/cmaj.081048

  20. Maurer MS, Mancini D. HFpEF: is splitting into distinct phenotypes by comorbidities the pathway forward? J Am Coll Cardiol. 2014; 64 (6): 550-552. Available in: http://dx.doi.org/10.1016/j.jacc.2014.06.010

  21. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018; 138 (9): 861-870. Available in: http://dx.doi.org/10.1161/circulationaha.118.034646

  22. Sleight P. The HOPE study (heart outcomes prevention evaluation). J Renin Angiotensin Aldosterone Syst. 2000; 1 (1): 18-20. Available in: http://dx.doi.org/10.3317/jraas.2000.002

  23. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362 (9386): 777-781. Available in: http://dx.doi.org/10.1016/s0140-6736(03)14285-7

  24. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019; 381 (17): 1609-1620. Available in: http://dx.doi.org/10.1056/nejmoa1908655

  25. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012; 380 (9851): 1387-1395. Available in: http://dx.doi.org/10.1016/s0140-6736(12)61227-6

  26. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370 (15): 1383-1392. Available in: http://dx.doi.org/10.1056/nejmoa1313731

  27. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385 (16): 1451-1461. Available in: http://dx.doi.org/10.1056/nejmoa2107038

  28. Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation [Internet]. 2021;144(16):1284–94. Available in: http://dx.doi.org/10.1161/circulationaha.121.056824

  29. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022; 387 (12): 1089-1098. Available in: http://dx.doi.org/10.1056/nejmoa2206286

  30. Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023; 389 (12): 1069-1084.

  31. Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014; 7 (6): 935-944. Available in: http://dx.doi.org/10.1161/circheartfailure.113.001229

  32. Brugts JJ, Radhoe SP, Aydin D, Theuns DA, Veenis JF. Clinical update of the latest evidence for CardioMEMS pulmonary artery pressure monitoring in patients with chronic heart failure: a promising system for remote heart failure care. Sensors (Basel). 2021; 21 (7): 2335. Available in: http://dx.doi.org/10.3390/s21072335

  33. Crea F. Mechanisms of heart failure with preserved ejection fraction, risk stratification of heart failure with reduced ejection fraction, and new light on resistance to diuretics in acute decompensated heart failure. Eur Heart J. 2021; 42 (43): 4405-4409. Available in: http://dx.doi.org/10.1093/eurheartj/ehab791




2020     |     www.medigraphic.com